Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
China SXT Pharmaceuticals Inc (SXTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: SXTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.06% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price - |
Price to earnings Ratio 0.01 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 |
52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 124.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 318.69% | Operating Margin (TTM) -76.95% |
Management Effectiveness
Return on Assets (TTM) 18.15% | Return on Equity (TTM) 57.63% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 190144853 | Price to Sales(TTM) 109.75 |
Enterprise Value 190144853 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 104.57 | Enterprise Value to EBITDA 29.92 | Shares Outstanding 116028000 | Shares Floating 488309 |
Shares Outstanding 116028000 | Shares Floating 488309 | ||
Percent Insiders 0.02 | Percent Institutions 0.01 |
Upturn AI SWOT
China SXT Pharmaceuticals Inc
Company Overview
History and Background
China SXT Pharmaceuticals Inc. (Nasdaq: SXTC) was founded in 2005 and is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of traditional Chinese medicines (TCMs) and Western medicines in China. The company has undergone several strategic shifts and expansions over the years to broaden its product portfolio and market reach. Significant milestones include its listing on the NASDAQ stock exchange and various product approvals.
Core Business Areas
- TCMs: Development, manufacturing, and sale of traditional Chinese medicines, which form a significant portion of their product line. These are often based on ancient formulations adapted for modern healthcare needs.
- Western Medicines: Manufacturing and marketing of certain Western medicines, complementing their TCM offerings and addressing a wider range of therapeutic areas.
- Research & Development: Investing in R&D to discover and develop new pharmaceutical products, both TCMs and Western medicines, to enhance their product pipeline and address unmet medical needs.
Leadership and Structure
Information on the specific leadership team and detailed organizational structure of China SXT Pharmaceuticals Inc. is subject to change and requires access to their latest corporate filings. Generally, such companies have a Board of Directors, a CEO, and various functional heads overseeing operations, R&D, sales, and finance.
Top Products and Market Share
Key Offerings
- Competitors: Numerous Chinese pharmaceutical companies, both large and small, that specialize in TCM, including state-owned enterprises and private firms.
- Description: China SXT Pharmaceuticals Inc. offers a range of TCM products targeting various ailments. Specific market share data for individual TCM products is not publicly disclosed, but the TCM market in China is vast and highly fragmented.
- Product Name: Various TCM Formulations
- Competitors: Domestic and international pharmaceutical companies operating in China, offering similar generic or branded Western medicines.
- Description: The company also produces and markets certain Western pharmaceuticals. Market share for these products would depend on the specific drug and therapeutic category.
- Product Name: Selected Western Medicines
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is one of the largest and fastest-growing globally. It is characterized by a dual focus on traditional Chinese medicine and modern Western pharmaceuticals. The industry is undergoing significant reforms aimed at improving drug quality, affordability, and access, with increasing government support for innovation and R&D. The aging population and rising healthcare expenditures further fuel market growth.
Positioning
China SXT Pharmaceuticals Inc. is positioned as a manufacturer and marketer of both TCM and Western medicines in China. Its competitive advantages may lie in its established TCM heritage, its R&D capabilities, and its distribution network within China. However, it faces intense competition from both domestic and international players.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals in China is estimated to be in the hundreds of billions of US dollars and is projected to continue growing. China SXT Pharmaceuticals Inc. aims to capture a segment of this market through its diverse product offerings and strategic expansion. Its current market share is relatively small compared to the overall TAM.
Upturn SWOT Analysis
Strengths
- Established presence in the Chinese pharmaceutical market.
- Portfolio of both Traditional Chinese Medicine (TCM) and Western medicines.
- Potential for product innovation and R&D.
Weaknesses
- Relatively small market share compared to larger domestic and international competitors.
- Dependence on the Chinese market.
- Potential for pricing pressures and regulatory changes.
- Limited brand recognition outside of specific niches.
Opportunities
- Growing demand for healthcare products in China.
- Government initiatives supporting the pharmaceutical industry.
- Expansion into new therapeutic areas or product lines.
- Potential for strategic partnerships or acquisitions.
Threats
- Intense competition from both domestic and international pharmaceutical companies.
- Increasing regulatory scrutiny and compliance requirements.
- Economic slowdowns or changes in government policies affecting healthcare spending.
- Intellectual property challenges and product counterfeiting.
Competitors and Market Share
Key Competitors
- China Pharma Holdings Inc. (CPHI)
- Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SS)
- Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Competitive Landscape
China SXT Pharmaceuticals Inc. faces a highly competitive landscape. While it has a presence in both TCM and Western medicine, it is a smaller player compared to state-owned giants and rapidly growing private enterprises. Its ability to innovate and effectively market its products will be crucial for its success against larger, more resourced competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for China SXT Pharmaceuticals Inc. has been influenced by market dynamics, product launches, and regulatory changes in China. Specific historical growth rates would be detailed in their financial reports.
Future Projections: Future growth projections for China SXT Pharmaceuticals Inc. are typically based on analyst estimates, market trends, and the company's strategic initiatives. These projections are subject to change and depend on various economic and industry factors.
Recent Initiatives: Recent initiatives might include new product development, market penetration strategies, or efforts to enhance operational efficiency. Specific details would be found in company announcements or investor relations materials.
Summary
China SXT Pharmaceuticals Inc. operates within the dynamic and expansive Chinese pharmaceutical market, offering both traditional Chinese medicines and Western pharmaceuticals. Its strengths lie in its established market presence and diversified product portfolio. However, the company faces significant challenges from intense competition and regulatory complexities. To thrive, it must focus on continuous innovation, strategic market penetration, and efficient operations to navigate the evolving healthcare landscape and secure a stronger market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Industry analysis reports
- Market research databases
Disclaimers:
This information is provided for informational purposes only and does not constitute financial advice. Stock market investments are subject to risk, and past performance is not indicative of future results. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China SXT Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-01-04 | Chairman of the Board & Co-CEO Mr. Feng Zhou | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 75 | Website https://www.sxtchina.com |
Full time employees 75 | Website https://www.sxtchina.com | ||
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.